Description: Diamyd Medical AB (publ) develops therapies for the treatment of autoimmune diabetes. The company develops Diamyd, an antigen-specific immunotherapy diabetes vaccine, which is in phase III clinical trial for the treatment of type 1 diabetes and latent autoimmune diabetes; and Remygen, an oral regenerative and immunomodulatory drug candidate, which is in phase I/II clinical trial for the treatment of autoimmune and type 2 diabetes. The company was formerly known as Diamyd Therapeutics AB and changed its name to Diamyd Medical AB (publ) in April 2013. Diamyd Medical AB (publ) was incorporated in 1984 and is based in Stockholm, Sweden.
Home Page: www.diamyd.com
Kungsgatan 29
Stockholm,
111 56
Sweden
Phone:
46 86 61 00 26
Officers
| Name | Title |
|---|---|
| Mr. Ulf Hannelius MBA, Ph.D. | CEO & Pres |
| Ms. Anna Styrud BSc | Chief Financial Officer |
| Ms. Martina Widman | Chief Operating Officer |
| Mr. Anton Lindqvist | Chief Scientific Officer |
| Eva Karlstrom | Chief Regulatory Affairs Officer |
| Christoph Nowak | Chief Medical Officer |
Exchange: ST
Country: SE
Currency: Swedish krone (kr)
| Forward PE: | 0 |
|---|---|
| Trailing PE: | 0 |
| Price-to-Book MRQ: | 5.6696 |
| Price-to-Sales TTM: | 2531.3528 |
| IPO Date: | |
| Fiscal Year End: | August |
| Full Time Employees: | 21 |